A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke

被引:350
作者
Amarenco, P. [1 ,2 ]
Kim, J. S. [20 ]
Labreuche, J. [1 ,2 ,11 ]
Charles, H. [1 ,2 ]
Abtan, J. [3 ]
Bejot, Y. [13 ]
Cabrejo, L. [1 ,2 ]
Cha, J-K [23 ]
Ducrocq, G. [3 ]
Giroud, M. [13 ]
Guidoux, C. [1 ,2 ]
Hobeanu, C. [1 ,2 ]
Kim, Y. J. [21 ]
Lapergue, B. [5 ]
Lavallee, P. C. [1 ,2 ]
Lee, B-C [26 ]
Lee, K-B [22 ]
Leys, D. [12 ]
Mahagne, M-H [14 ]
Meseguer, E. [1 ,2 ]
Nighoghossian, N. [15 ,16 ]
Pico, F. [17 ]
Samson, Y. [6 ]
Sibon, I [18 ]
Steg, P. G. [3 ,27 ,28 ]
Sung, S-M [24 ,25 ]
Touboul, P. J. [1 ,2 ]
Touze, E. [19 ]
Varenne, O. [4 ]
Vicaut, E. [9 ]
Yelles, N. [7 ]
Bruckert, E. [8 ,10 ]
机构
[1] Hop Xavier Bichat, Lab Vasc Translat Sci, Dept Neurol,INSERM Unite 1148, Dept Hosp Univ Fibrose Inflammat Remodelage,AP HP, Paris, France
[2] Hop Xavier Bichat, Lab Vasc Translat Sci, Stroke Ctr,INSERM Unite 1148, Dept Hosp Univ Fibrose Inflammat Remodelage,AP HP, Paris, France
[3] Hop Xavier Bichat, Lab Vasc Translat Sci, Dept Cardiol,INSERM Unite 1148, Dept Hosp Univ Fibrose Inflammat Remodelage,AP HP, Paris, France
[4] Univ Paris, Cochin Hosp, Dept Cardiol, Paris, France
[5] Foch Hosp, Dept Neurol, Suresnes, France
[6] Univ Paris Diderot, Fernand Widal Hosp, Hop Pitie Salperriere,Dept Biostat, AP HP,Sorbonne Paris Cite,Urgences Cerebrovascula, Suresnes, France
[7] Univ Paris Diderot, Fernand Widal Hosp, Hop Pitie Salperriere,AP HP, Sorbonne Paris Cite,Ctr Pharmacoepidemiol,Dept Bi, Suresnes, France
[8] Univ Paris Diderot, Fernand Widal Hosp, Hop Pitie Salperriere,AP HP, Sorbonne Paris Cite,Dept Endocrinol,Dept Biostat, Suresnes, France
[9] Univ Paris Diderot, Fernand Widal Hosp, Hop Pitie Salperriere, AP HP,Sorbonne Paris Cite,Dept Biostat, Suresnes, France
[10] Sorbonne Univ, Dept Endocrinol, Paris, France
[11] Sante Publ Epidemiol & Qualite Soins, Equipe Accueil EA2694, Lille, France
[12] Univ Lille, Ctr Hosp Univ CHU Lille, Stroke Unit, Dept Neurol, Lille, France
[13] Univ Burgundy, Univ Hosp Dijon, Dept Neurol, Dijon, France
[14] Pasteur Hosp, Stroke Unit, Nice, France
[15] Lyon Univ, Dept Neurol, Hospices Civils Lyon, Lyon, France
[16] Lyon Univ, Stroke Ctr, Lyon, France
[17] Versailles Univ Hosp, Dept Neurol, Versailles, France
[18] Univ Bordeaux, Pellegrin Tripode Hosp, Dept Vasc Neurol, Bordeaux, France
[19] Univ Caen Normandie, CHU Caen Normandie, INSERM Unite 1237, Cyceron,Dept Neurol, Caen, France
[20] Catholic Univ Korea, Eunpyeong St Marys Hosp, Asan Med Ctr, Seoul, South Korea
[21] Catholic Univ Korea, Eunpyeong St Marys Hosp, Dept Neurol, Seoul, South Korea
[22] Soonchunhyang Univ, Coll Med, Dept Neurol, Seoul, South Korea
[23] Dong A Univ Hosp, Busan, South Korea
[24] Pusan Natl Univ Hosp, Dept Neurol, Busan, South Korea
[25] Pusan Natl Univ Hosp, Stroke Ctr, Busan, South Korea
[26] Hallym Univ, Sacred Heart Hosp, Dept Neurol, Anyang, South Korea
[27] Imperial Coll, Natl Heart & Lung Inst, London, England
[28] Royal Brompton Hosp, Inst Cardiovasc Med & Sci, London, England
关键词
AGGRESSIVE REDUCTION; ATORVASTATIN; PREVENTION; ATTACK; METAANALYSIS; TRIAL; RISK;
D O I
10.1056/NEJMoa1910355
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The use of intensive lipid-lowering therapy by means of statin medications is recommended after transient ischemic attack (TIA) and ischemic stroke of atherosclerotic origin. The target level for low-density lipoprotein (LDL) cholesterol to reduce cardiovascular events after stroke has not been well studied. Methods In this parallel-group trial conducted in France and South Korea, we randomly assigned patients with ischemic stroke in the previous 3 months or a TIA within the previous 15 days to a target LDL cholesterol level of less than 70 mg per deciliter (1.8 mmol per liter) (lower-target group) or to a target range of 90 mg to 110 mg per deciliter (2.3 to 2.8 mmol per liter) (higher-target group). All the patients had evidence of cerebrovascular or coronary-artery atherosclerosis and received a statin, ezetimibe, or both. The composite primary end point of major cardiovascular events included ischemic stroke, myocardial infarction, new symptoms leading to urgent coronary or carotid revascularization, or death from cardiovascular causes. Results A total of 2860 patients were enrolled and followed for a median of 3.5 years; 1430 were assigned to each LDL cholesterol target group. The mean LDL cholesterol level at baseline was 135 mg per deciliter (3.5 mmol per liter), and the mean achieved LDL cholesterol level was 65 mg per deciliter (1.7 mmol per liter) in the lower-target group and 96 mg per deciliter (2.5 mmol per liter) in the higher-target group. The trial was stopped for administrative reasons after 277 of an anticipated 385 end-point events had occurred. The composite primary end point occurred in 121 patients (8.5%) in the lower-target group and in 156 (10.9%) in the higher-target group (adjusted hazard ratio, 0.78; 95% confidence interval, 0.61 to 0.98; P=0.04). The incidence of intracranial hemorrhage and newly diagnosed diabetes did not differ significantly between the two groups. Conclusions After an ischemic stroke or TIA with evidence of atherosclerosis, patients who had a target LDL cholesterol level of less than 70 mg per deciliter had a lower risk of subsequent cardiovascular events than those who had a target range of 90 mg to 110 mg per deciliter. (Funded by the French Ministry of Health and others; Treat Stroke to Target ClinicalTrials.gov number, NCT01252875.)
引用
收藏
页码:9 / 19
页数:11
相关论文
共 17 条
[1]  
Agence Francaise de Securite Sanitaire des Produits de Sante, 2005, Rev Prat, V55, P1788
[2]   Transient ischemic attack - Proposal for a new definition. [J].
Albers, GW ;
Caplan, LR ;
Easton, JD ;
Fayad, PB ;
Mohr, JP ;
Saver, JL ;
Sherman, DG .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (21) :1713-1716
[3]   Five-Year Risk of Stroke after TIA or Minor Ischemic Stroke [J].
Amarenco, P. ;
Lavallee, P. C. ;
Tavares, L. Monteiro ;
Labreuche, J. ;
Albers, G. W. ;
Abboud, H. ;
Anticoli, S. ;
Audebert, H. ;
Bornstein, N. M. ;
Caplan, L. R. ;
Correia, M. ;
Donnan, G. A. ;
Ferro, J. M. ;
Gongora-Rivera, F. ;
Heide, W. ;
Hennerici, M. G. ;
Kelly, P. J. ;
Kral, M. ;
Lin, H. -F. ;
Molina, C. ;
Park, J. M. ;
Purroy, F. ;
Rothwell, P. M. ;
Segura, T. ;
Skoloudik, D. ;
Steg, P. G. ;
Touboul, P. -J. ;
Uchiyama, S. ;
Vicaut, E. ;
Wang, Y. ;
Wong, L. K. S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (23) :2182-2190
[4]   Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack - The stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial [J].
Amarenco, Pierre ;
Goldstein, Larry B. ;
Szarek, Michael ;
Sillesen, Henrik ;
Rudolph, Amy E. ;
Callahan, Alfred, III ;
Hennerici, Michael ;
Simunovic, Lisa ;
Zivin, Justin A. ;
Welch, K. Michael A. .
STROKE, 2007, 38 (12) :3198-3204
[5]   Treat stroke to target trial design: First trial comparing two LDL targets in patients with atherothrombotic strokes [J].
Amarenco, Pierre ;
Kim, Jong S. ;
Labreuche, Julien ;
Giroud, Maurice ;
Lee, Byung-Chul ;
Mahagne, Marie-Helene ;
Nighoghossian, Norbert ;
Simon, Tabassome ;
Steg, Philippe Gabriel ;
Touboul, Pierre-Jean ;
Vicaut, Eric ;
Yelles, Nessima ;
Bruckert, Eric .
EUROPEAN STROKE JOURNAL, 2019, 4 (03) :271-280
[6]   Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention [J].
Amarenco, Pierre ;
Labreuche, Julien .
LANCET NEUROLOGY, 2009, 8 (05) :453-463
[7]  
Amarenco P, 2006, NEW ENGL J MED, V355, P549
[8]  
[Anonymous], 2013, CLIN PRACTICE GUIDEL, P231
[9]   Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials [J].
Baigent, C. ;
Blackwell, L. ;
Emberson, J. ;
Holland, L. E. ;
Reith, C. ;
Bhala, N. ;
Peto, R. ;
Barnes, E. H. ;
Keech, A. ;
Simes, J. ;
Collins, R. .
LANCET, 2010, 376 (9753) :1670-1681
[10]  
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3